Biotech Showcase is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Scott Requadt
Venture Partner at Blackstone


Scott Requadt, JD, MBA, is currently CEO of a privately-held cell therapy company that recently closed a significant financing. Scott was previously a Managing Director at Clarus (now Blackstone Life Sciences), where he sourced, led and managed investments spanning therapeutics, medtech and diagnostics. He remains a Venture Partner at Blackstone Life Sciences. Scott has over 17 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals (acquired by J&J), and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Scott currently also serves on the Boards of ESSA Pharmaceuticals (Nasdaq: EPIX) and VBI Vaccines (Nasdaq: VBIV). He has previously been active on the Boards of Avrobio (Nasdaq: AVRO), Edev s.a.r.l, TyRx (acquired by Medtronic), Catabasis (Nasdaq: CATB), Oxford Immunotec (Nasdaq: OXFD), Link Medicine (acquired by AstraZeneca), and Biolex Therapeutics.

Scott Requadt's Network

Agenda Sessions

  • Cell and gene therapy: The financing surge - Hilton Union Square